7 papers in the library · 546 citations · publishing 2022-2026
PsyArXiv March 26, 2026 Broc A. Pagni, Stephen Ross, Sarah E. Mennenga et al. preprint
Safety and Efficacy of Psilocybin-Assisted Therapy for Alcohol Use Disorder: Open-Label Extension of a Phase II Randomized Controlled Trial
Frontiers in Psychology 2024 Kelley C O'Donnell, Lauren Okano, Michael Alpert et al.
Results from multiple recent studies support further evaluation of 3,4-methylenedioxymethamphetamine (MDMA) in conjunction with psychotherapy (i.e., MDMA-Assisted Therapy) in the treatment of post-traumatic stress disorder (PTSD). In two Phase 3 trials, MDMA-Assisted Therapy comprised a short-term, intensive psychotherapy that included three sessions directly facilitated by MDMA (referred to as...
Psychedelic Med (New Rochelle) December 13, 2023 Kelley C O'Donnell, Daniel E. Roberts, Terence H. W. Ching et al. 13 citations
What Is in a Name? The Many Meanings of "Psychedelic".
JAMA August 31, 2023 Charles L. Raison, Gerard Sanacora, Joshua Woolley et al. 493 citations
Importance Psilocybin shows promise as a treatment for major depressive disorder (MDD). Objective To evaluate the magnitude, timing, and durability of antidepressant effects and safety of a single dose of psilocybin in patients with MDD. Design, Setting, and Participants In this phase 2 trial conducted between December 2019 and June 2022 at 11 research sites in the US, participants were...
Contemporary Clinical Trials December 1, 2022 Kelley C O'Donnell, Sarah E. Mennenga, Lindsey T. Owens et al. 24 citations
Several lines of evidence suggest that classic psychedelics (5-HT2A receptor agonists or partial agonists) such as psilocybin might facilitate behavior change in individuals with substance use disorders. We conducted a multi-site, double-blind, randomized controlled trial (RCT) to assess the effects of psilocybin-assisted psychotherapy in alcohol-dependent volunteers. In addition to a...
Journal of Affective Disorders September 1, 2022 David S. Mathai, Scott M Lee, Victoria Mora et al. 16 citations
Given increasing community-based and off-label use of ketamine for psychiatric indications, we examined current informed consent processes from a convenience sample of outpatient ketamine clinics to identify areas of congruence with current evidence and opportunities for growth. Using a rubric developed from existing practice guidelines, we conducted an exploratory analysis of informed consent...
Kelley C O'Donnell, Michael Alpert, Lauren Okano et al. preprint
Results from multiple recent studies support the use of 3,4-methylenedioxymethamphetamine (MDMA) in conjunction with psychotherapy (i.e., MDMA-Assisted Therapy) in the treatment of post-traumatic stress disorder (PTSD). In two Phase 3 trials, MDMA-Assisted Therapy comprised a short-term, intensive psychotherapy that included three sessions directly facilitated by MDMA (referred to as...